Abstract:In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics especially peptides and proteins. In the intervening period, analysis of the preclinical and clinical trial failures of many purported platform technologies has led to reflection on the true status of the field and reigning in of expectations. Oral formulations of semaglutide, octreotide, and salmon calcitonin have completed Phase III trials, with oral semaglutide being approved by the FDA in 2019. The progress made with oral peptide formulations based on traditional permeation enhancers is against a background of low and variable oral bioavailability values of ~1%, leading to a current perception that only potent peptides with a viable cost of synthesis can be realistically considered. Desirable features of candidates should include a large therapeutic index, some stability in the GI tract, a long elimination half-life, and a relatively low clearance rate. Administration in nanoparticle formats have largely disappointed, with few prototypes reaching clinical trials: insufficient particle loading, lack of controlled release, low epithelial particle uptake, and lack of scalable synthesis being the main reasons for discontinuation. Disruptive technologies based on engineered devices promise improvements, but scale-up and toxicology aspects are issues to address. In parallel, medicinal chemists are synthesizing stable hydrophobic macrocyclic candidate peptides of lower molecular weight and with potential for greater oral bioavailability than linear peptides, but perhaps without the same requirement for elaborate drug delivery systems. In summary, while there have been advances in understanding the limitations of peptides for oral delivery, low membrane permeability, metabolism, and high clearance rates continue to hamper progress.

Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals

Lipid-Based Nanoparticles as Oral Drug Delivery Systems: Overcoming Poor Gastrointestinal Absorption and Enhancing Bioavailability of Peptide and Protein Therapeutics

Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Advances in Lipid-Based Drug Delivery: Enhancing Efficiency for Hydrophobic Drugs

Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Multi-strategic approaches for enhancing active transportation using self-emulsifying drug delivery system

Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery

Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide

Long acting injectable formulations: the state of the arts and challenges of poly(lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal

Challenges and opportunities in delivering oral peptides and proteins

The Advances in Phospholipids-Based Phase Separation Gels for the Sustained Release of Peptides, Proteins, and Chemotherapeutics

A Window for Enhanced Oral Delivery of Therapeutics via Lipid Nanoparticles

The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs

Oral Delivery of Protein Drugs via Lysine Polymer‐Based Nanoparticle Platforms

Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals

Ionic Liquids: Promising Approach for Oral Drug Delivery

Orally administered self-emulsifying drug delivery system in disease management: advancement and patents